Clinical Trials Logo

Myocardial Infarction, Acute clinical trials

View clinical trials related to Myocardial Infarction, Acute.

Filter by:

NCT ID: NCT04146701 Recruiting - Sepsis Clinical Trials

Metabolomics and Microbiomics in Cardiovascular Diseases

MEMORIA
Start date: February 1, 2019
Phase:
Study type: Observational [Patient Registry]

"MEtabolomics and MicrObiomics in caRdIovAscular diseases Mannheim (MEMORIAM) " is a single-center, prospective and observational study investigating to identify disease-specific metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular diseases. High-risk cardiovascular diseases comprise patients suffering from acute heart failure (AHF), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy.

NCT ID: NCT03957005 Recruiting - Clinical trials for Myocardial Infarction, Acute

Cardiovascular Risk Assessment Model in Patients With MI

Start date: November 6, 2018
Phase:
Study type: Observational

This study aims to investigate life-style and psycho social factors of major cardiovascular events in patients with myocardial infarction in three different provinces of Iran and to design a risk assessment chart for major cardiovascular events in patients with MI.

NCT ID: NCT03809689 Recruiting - Clinical trials for Myocardial Infarction, Acute

Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The study is about exploring physiological angiogenesis linked to tissue repair in patients with acute heart infarction or chronic heart ischemia by means of 68Ga-NODAGA-RGD PET/CT imaging.

NCT ID: NCT03621111 Recruiting - Clinical trials for Myocardial Infarction, Acute

A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction

IM-ADHERENCE
Start date: February 19, 2018
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to evaluate the effectiveness of the active involvement of Community Pharmacists in improving adherence to medical prescriptions in patients with acute myocardial infarction (AMI), reducing the rate of adverse events and / or re-admissions due to cardiovascular disease and reducing overall health costs. The Hospital and Community Pharmacists will collaborate with each other, the patients, heart specialists and primary care physicians, throughout 12 months from the hospital discharge.

NCT ID: NCT03600259 Recruiting - Clinical trials for Myocardial Infarction, Acute

Tianjin Inpatient Acute Myocardial Infarction Registry

TAMI
Start date: January 1, 2018
Phase:
Study type: Observational

Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

NCT ID: NCT03412435 Recruiting - Coronary Stenosis Clinical Trials

Asan Medical Center Myocardial Infarction Registry

Asan-MI
Start date: April 27, 2018
Phase:
Study type: Observational

This study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in Asan medical center, Korea.

NCT ID: NCT03317691 Recruiting - Clinical trials for Artificial Intelligence

The ALERT-Pilot Study

Start date: October 20, 2017
Phase: N/A
Study type: Observational

the algorithm of artificial intelligent to diagnose myocardial infarction through prior surgery Electrocardiogram was established. The accuracy of using artificial intelligent to diagnose acute ST-segment elevation myocardial infarction and judge criminal vascular was evaluated.